-
Thousands of people are treated every day!
Time of Update: 2022-05-25
The hospital revealed that up to now, the Beijing Institute of Pediatrics' Internet Hospital has served 238,000 patients for follow-up visits, and delivered 145,000 cases of medicines, covering In 31 provinces and 328 prefecture-level cities across the country, the daily volume of diagnosis and treatment is about 1,000 .
-
What happened to those pharmacies that entered the Gaoji bowl?
Time of Update: 2022-05-25
Acquired Wanmen Store Beginning in 2017, Hillhouse established Gaoji Medical, and based on this, began a major acquisition in the pharmaceutical retail industry .
-
From Yunnan Baiyao to Huadong Medicine, will investing in "not doing a good job" wrong?
Time of Update: 2022-05-25
Affected by the medical beauty business, Sihuan Pharmaceutical's revenue and net profit in 2021 will increase by 1383.
In addition to Huadong Medicine and Sihuan Medicine, which are already well-known in the field of medical beauty, the newly entered Teyi Pharmaceutical, Yunnan Baiyao, Jiangsu Wuzhong, Xingkerong Pharmaceutical and other companies also have a background in the pharmaceutical industry .
-
Simcere broke out with 15 class 1 new drugs and 11 new products
Time of Update: 2022-05-25
Currently, 18 innovative drugs (15 category 1 new drugs) are in the approved clinical stage and above, and 4 innovative drugs are expected to be launched; , 17 varieties have been reviewed (6 first), 5 are planned to be included in the seventh batch of centralized procurement, and the first imitation of $9.
-
The innovative medical device "Magnetic Resonance Imaging System" was approved for listing
Time of Update: 2022-05-25
The State Food and Drug Administration also released a list of approved innovative medical device products .
According to the list, the "Magnetic Resonance Imaging System" is the 16th innovative medical device approved this year .
-
Investment trend of improved new drugs: predict future growth points and risk points!
Time of Update: 2022-05-25
On the one hand, because there are very few domestic companies that make Class 1 innovative drugs; on the other hand, improved new drugs re-innovate the already marketed drugs to meet clinical needs, achieve efficiency enhancement and detoxification, improve patient compliance, and enhance product intrinsics.
-
"Internet +" medical treatment loses to face-to-face?
Time of Update: 2022-05-25
Under the epidemic, the Second Hospital of Lanzhou University opened an Internet hospital medical service, providing consultation, online follow-up (prescribing medicines, prescribing examinations), examination appointments, drug delivery and other services.
-
National Medical Insurance Administration: China has vaccinated 3.2 billion doses of vaccines, costing more than 120 billion yuan
Time of Update: 2022-05-25
Recently, the responsible comrades of the relevant departments of the National Medical Insurance Bureau were interviewed by reporters on issues such as the price of new coronavirus vaccines and the impact of purchasing vaccines on medical insurance funds that are generally concerned by the society .
-
In 2025, grass-roots traditional Chinese medicine will achieve five "full coverage"!
Time of Update: 2022-05-24
The development of grass-roots traditional Chinese medicine has ushered in good news . The "14th Five-Year Plan" action plan proposes to achieve five "full coverage" by 2025; to select and release
-
Chinese patent medicines "seize" the retail market of cough medicines, and many varieties grow against the trend
Time of Update: 2022-05-24
In 2020, the sales growth of physical pharmacies in key cities and the top 5 varieties of cough medicines Data source: Minet.
-
WHO: Chinese medicine can effectively treat new coronary pneumonia
Time of Update: 2022-05-24
The World Health Organization recently released the report of the "World Health Organization Expert Evaluation Meeting on the Treatment of New Coronary Pneumonia with Traditional Chinese Medicine" .
The meeting evaluated the clinical application, research and evidence-based evaluation reports provided by the Chinese expert group .
-
What is the adjustment logic of the global TOP10 pharmaceutical companies for spin-off, divestiture and sale, and structural adjustment?
Time of Update: 2022-05-22
In April, Novartis CEO Vas Narasimhan announced a new organizational structure and operating model to support the company's innovation, growth and productivity goals over the next decade .
-
Overview and prospect of my country's mask industry development, production capacity has increased significantly
Time of Update: 2022-05-22
Driven by factors such as policy support, China's mask production capacity and output have risen rapidly, effectively solving the problem of tight supply and contributing to the prevention and control of the global new crown pneumonia epidemic .
-
Officials encourage this "non-drug" to enter medical insurance pharmacies
Time of Update: 2022-05-22
For example, the Ganzhou Municipal Medical Insurance Bureau in Jiangxi Province once issued a notice requiring all designated retail pharmacies to promptly remove prohibited non-pharmaceutical products from the shelves.
-
Centralized procurement of Chinese patent medicines in 19 provinces in Hubei, and began to allocate procurement volumes
Time of Update: 2022-05-22
Work Notice", with regard to the 17 product groups clearly identified in the centralized procurement of the Chinese Patent Medicine Alliance in 19 Hubei Provinces, to carry out the agreed procurement volume allocation for medical institutions in Shanxi Province .
-
The tertiary hospital issued a set of adopted drug assessment indicators: the proportion of use, the proportion of completion!
Time of Update: 2022-05-22
This extended indicator: the numerator is the number of varieties of the selected drugs that the hospital has completed the centralized procurement of drugs organized by the state in the purchase and sales contracts with volume .
-
Nearly 2 billion "bone care needles"!
Time of Update: 2022-05-22
On April 6, the official website of the State Food and Drug Administration showed that China Resources Shuanghe was approved to market as a concentrated solution of zoledronic acid for injection, which was produced in imitation of Category 4 .
-
Opportunities and challenges coexist in my country's pharmaceutical foreign trade in 2022
Time of Update: 2022-05-22
However, the current new crown pneumonia epidemic is still spreading, the international situation is still changing, the development of pharmaceutical foreign trade is facing many risks and challenges, and there are many uncertainties in the future situation .
-
The focus of centralized procurement in 2022: no less than 100 drugs in each province, including Chinese patent medicine, orthopedics, oral cavity, and balloon
Time of Update: 2022-05-22
The National Medical Insurance Bureau has clarified that by the end of 2022, the number of drug varieties collected by provinces (including inter-provincial alliances) should not be less than 100, and must include chemical drugs, proprietary Chinese medicines, orthopedic trauma, oral implants, drug balloons and other consumables .
-
Chinese medicine companies that invest more than 100 million yuan in research and development, is the money used correctly?
Time of Update: 2022-05-22
Table 1: Some listed Chinese medicine companies with R&D investment of over 100 million yuan (data source: annual report) CDE data shows that in 2021, CDE accepted a total of about 1,360 Chinese medicine applications, including 60 new drug applications, an increase of 32 applications compared with 2020.
